Rosuvastatin slows subclinical atherosclerosis in HIV group with normal LDL-cholesterol

Rosuvastatin for 96 weeks significantly slowed progression of subclinical atherosclerosis — as measured by common carotid artery intima-media thickness (CCA-IMT) — in a double-blind placebo-controlled trial. Participants had normal low-density lipoprotein cholesterol (LDL-C) before treatment began, but the statin further lowered LDL-C, according to the ...

November 24, 2016
EATG  EATG  News